Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,324 across all filing types
Latest filing 2022-11-15 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Major shareholder disclosure
Report Publication Announcement Classification · 98% confidence The document text is extremely short (103 characters) and explicitly states "Major shareholder disclosure" and directs the user to an attachment on 'www.newsweb.no'. This strongly suggests the document is an announcement about the disclosure rather than the disclosure itself. According to Rule 2 (The 'Menu vs Meal' Rule), a short announcement pointing to an external report should be classified as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since 'Major shareholder disclosure' is a specific type of regulatory filing, and the text is merely pointing to the actual disclosure, RPA is the most appropriate classification for the announcement itself, as it announces the publication of information.
2022-11-15 English
Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting
Regulatory Filings Classification · 99% confidence The document is a press release dated November 7, 2022, announcing that the United States Centers for Medicare & Medicaid Services (CMS) has released final payment rates and made complexity adjustments for Blue Light Cystoscopy (BLC) with Cysview in hospital outpatient and ambulatory surgical center settings, effective January 1, 2023. This is a specific announcement regarding regulatory/reimbursement changes impacting the company's product, rather than a comprehensive financial report (like 10-K or IR) or a general regulatory filing (RNS). It details specific financial/reimbursement outcomes, which aligns best with an 'Earnings Release' (ER) if it were quarterly results, but since it is a specific operational/regulatory announcement with financial implications, it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard announcement, or potentially 'Capital/Financing Update' (CAP) due to the direct impact on revenue streams, but RNS is the most appropriate catch-all for significant, non-periodic operational news releases that aren't explicitly covered elsewhere. Upon review of the definitions, this is a press release announcing a significant operational/regulatory development (CMS reimbursement change). It is not a 10-K, AR, IR, or ER (which focuses on P&L/Balance Sheet). It is not a management change (MANG) or director dealing (DIRS). It is a specific announcement of a regulatory outcome that impacts revenue. Given the options, 'Regulatory Filings' (RNS) is the best fit for a press release detailing a specific regulatory decision (CMS rule) that is not a standard periodic report or a specific transaction announcement (like DIV or SHA).
2022-11-07 English
Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting
Regulatory Filings Classification · 99% confidence The document is a press release dated November 7, 2022, announcing that the United States Centers for Medicare & Medicaid Services (CMS) has released final payment rates and improved reimbursement for Blue Light Cystoscopy (BLC) with Cysview. This type of announcement, detailing specific regulatory or operational updates that impact revenue or access, is characteristic of an Earnings Release (ER) or a general announcement. Since it is a formal announcement of a significant operational/financial development (reimbursement rates) rather than a full periodic report (10-K, IR) or a management discussion (MDA), it fits best as an Earnings Release (ER) which often includes key operational highlights and financial implications, or potentially a Regulatory Filing (RNS) if it were less focused on financial impact. Given the focus on CMS payment rates and the CEO quote, ER is the most appropriate fit among the specific options, as it functions as a material update outside of standard quarterly reporting.
2022-11-07 English
Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press Release" and announces a specific corporate event: Photocure's partner enrolling the first patient in a Phase III trial for Hexvix in China. This type of announcement, detailing operational progress, clinical trial updates, and partnership milestones, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing operational news rather than a formal financial statement (like 10-K or IR) or a transcript (CT), and it is not specifically about management changes (MANG), director dealings (DIRS), or capital structure (CAP), the most appropriate classification is Earnings Release (ER) if it were tied to a reporting period, or RNS if it's a general operational update. Given the context of financial reporting databases, press releases announcing significant operational milestones often fall under ER if they contain key performance indicators or are released near reporting dates, or RNS if they are purely informational. Since this is a specific operational update about a clinical trial milestone, and not a summary of financial results, RNS (Regulatory Filings/General Announcement) is the safest general category, although ER is also plausible if this is considered a key business update. However, looking at the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Therefore, it fits best as a general regulatory announcement or operational update, which aligns with RNS.
2022-11-04 English
Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press Release" and announces a specific corporate/clinical event: the enrollment of the first patient in a Phase III trial for Hexvix by partner Asieris. It contains standard press release elements like date, location, company background, and contact information. This type of announcement, which is not a formal regulatory filing like a 10-K, a detailed financial report (IR), or a management change (MANG), fits best under the general category for corporate news announcements. Since it is a specific operational/clinical update that doesn't fit the other specialized codes (like DIV, CAP, DIRS, etc.), the most appropriate classification is Regulatory Filings (RNS) as a general corporate announcement/press release, or potentially Investor Presentation (IP) if it were a slide deck, but given the format, RNS is the best fit for a general press release not covered elsewhere.
2022-11-04 English
Major shareholder disclosure in Photocure ASA
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "Standard form for notification of major holdings" and contains structured fields detailing the acquisition/disposal of voting rights, the identity of the person subject to notification (Skandinaviska Enskilda Banken AB (publ)), the issuer (Photocure ASA), and the date the threshold was crossed (2022-11-02). This format is characteristic of regulatory filings related to changes in significant share ownership, which corresponds directly to the Major Shareholding Notification category (MRQ) under European transparency directives (referenced by Directive 2004/109/EC). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory announcement (RNS), but a specific disclosure type.
2022-11-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.